Pfizer nets first AIDS patent in India

Pfizer cleared a big milestone in India today: The company became the first to get patent protection for an AIDS drug there. The new patent covers Celzentry, or maraviroc, a new, first-in-class HIV remedy that was approved by the U.S. FDA in August.

Pfizer's victory follows several other attempts, including GlaxoSmithKline's bid for a patent on Combivir; opposition from patient groups prompted GSK to withdraw its application last year.

- read the report from the Economic Times
- see this chart of HIV drug patent applications and their status in the Business Standard

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.